Connection

JOHN KIRKWOOD to Membrane Proteins

This is a "connection" page, showing publications JOHN KIRKWOOD has written about Membrane Proteins.
Connection Strength

0.816
  1. Unfolding the mutational landscape of human melanoma. J Invest Dermatol. 2015 Mar; 135(3):659-662.
    View in: PubMed
    Score: 0.231
  2. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 Jan 01; 62(1):213-8.
    View in: PubMed
    Score: 0.093
  3. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 Sep 01; 60(17):4946-52.
    View in: PubMed
    Score: 0.085
  4. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther. 2018 02 01; 19(2):132-137.
    View in: PubMed
    Score: 0.070
  5. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
    View in: PubMed
    Score: 0.054
  6. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
    View in: PubMed
    Score: 0.053
  7. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010 Sep 27; 207(10):2175-86.
    View in: PubMed
    Score: 0.042
  8. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 01; 182(9):5240-9.
    View in: PubMed
    Score: 0.039
  9. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 01; 174(3):1751-9.
    View in: PubMed
    Score: 0.029
  10. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res. 2003 Oct 01; 63(19):6506-15.
    View in: PubMed
    Score: 0.026
  11. Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. J Extracell Vesicles. 2021 02; 10(4):e12063.
    View in: PubMed
    Score: 0.022
  12. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gaq and Ga11 and kill uveal melanoma cells. Cancer Biol Ther. 2019; 20(5):700-710.
    View in: PubMed
    Score: 0.019
  13. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res. 1996 Aug; 2(8):1263-74.
    View in: PubMed
    Score: 0.016
  14. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012 Feb 15; 72(4):887-96.
    View in: PubMed
    Score: 0.012
  15. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J Immunol. 2011 Jan 01; 186(1):312-22.
    View in: PubMed
    Score: 0.011
  16. Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol. 2007 Dec 01; 179(11):7932-40.
    View in: PubMed
    Score: 0.009
  17. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment. Mol Imaging. 2003 Jan; 2(1):65-73.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.